This study is looking for patients who are currently using long acting insulin shots with or without oral antidiabetic medications for Type 2 Diabetes. It will look at replacing the patient’s current daily long acting insulin shots with one of two potential weekly injections instead. One of the possible weekly injections is Icodec, a once weekly long acting insulin. The other possible weekly injection is IcoSema. IcoSema is a combination of Icodec and an approved weekly injection called Semaglutide.
If you qualify, you will receive study-related care and study medication or an approved medication at no charge. You may also receive compensation for travel expenses.
To take part in the study, participants should be: